Dr Brent S Follweiler, MD | |
62 Preble Lane, Brooklin, ME 04616 | |
(207) 359-2075 | |
Not Available |
Full Name | Dr Brent S Follweiler |
---|---|
Gender | Male |
Speciality | Anesthesiology |
Location | 62 Preble Lane, Brooklin, Maine |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1952418949 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207L00000X | Anesthesiology | MD029214L (Pennsylvania) | Secondary |
207L00000X | Anesthesiology | 015571 (Maine) | Primary |
207L00000X | Anesthesiology | 0420011062 (Vermont) | Secondary |
Mailing Address | Practice Location Address |
---|---|
Dr Brent S Follweiler, MD 62 Preble Lane, Brooklin, ME 04616 Ph: (207) 359-2075 | Dr Brent S Follweiler, MD 62 Preble Lane, Brooklin, ME 04616 Ph: (207) 359-2075 |
News Archive
Cushing disease is a hormone disorder that causes a diverse array of symptoms, including fat accumulation, high blood pressure, osteoporosis, muscle wasting, and ultimately death. It is caused by a tumor in the anterior pituitary gland that results in the secretion of excess amounts of adrenocorticotropic hormone (ACTH). Treatment options are essentially limited to surgical resection. However, tumors commonly recur, meaning that new treatment options are needed.
Seegene, Inc., a leader in multi-pathogen diagnostic testing, today announced that it has been awarded patent in the U.S. and Europe for Annealing Control Primer (ACP), a new technology for amplifying a specific region of a gene with much higher specificity and reproducibility than conventional approaches.
St. Jude Medical, Inc., a global medical device company, today announced the first post-approval implant of the Nanostimâ„¢ leadless pacemaker in the U.K. The world's first retrievable leadless pacemaker was implanted at St. Bartholomew's Hospital in London by Professor Richard Schilling.
Florida is still in dire need of more nurses and is among the top states in the nation experiencing a shortage.
Eleven Biotherapeutics, a biopharmaceutical company designing and engineering novel and differentiated protein-based biotherapeutics for ocular diseases, announced today positive topline clinical results from a 6-week randomized, double-masked, placebo-controlled Phase 1b/2a study of EBI-005 in patients with dry eye disease.
› Verified 4 days ago